Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,901 to 3,920 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| CT Coronary Angiogram vs Standard Care: serious adverse events | 18 of 877 10 of 871 | 0.9 points -0.3 to 2.2 | 1,748 | NCT02284191 Rapid Assessment of Potential Ischaemic Heart Disease With CTCA |
| Vadadustat vs Darbepoetin Alfa: deaths from any cause | 180 of 878 168 of 870 | 1.2 points -2.6 to 4.9 | 1,748 | NCT02648347 Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease |
| Vadadustat vs Darbepoetin Alfa: serious adverse events | 573 of 878 561 of 870 | 0.8 points -3.7 to 5.2 | 1,748 | NCT02648347 Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease |
| Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): deaths from any cause | 41 of 879 42 of 868 | -0.2 points -2.2 to 1.9 | 1,747 | NCT00869206 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement |
| Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): serious adverse events | 96 of 879 103 of 868 | -0.9 points -3.9 to 2.0 | 1,747 | NCT00869206 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement |
| Creatine vs Placebo: serious adverse events | 315 of 874 347 of 867 | -4.0 points -8.5 to 0.6 | 1,741 | NCT00449865 NET-PD LS-1 Creatine in Parkinson's Disease |
| CABG vs PCI With DES: Repeat Revascularization (PCI and/or CABG). | 50 of 849 120 of 891 | -7.6 points -10.4 to -4.8 | 1,740 | NCT00114972 SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries |
| CABG vs PCI With DES: Primary Clinical Endpoint of 12-Month Binary MACCE. | 105 of 849 159 of 891 | -5.5 points -8.8 to -2.1 | 1,740 | NCT00114972 SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries |
| CABG vs PCI With DES: 12-month Composite Safety Endpoint. | 65 of 849 68 of 891 | 0.0 points -2.5 to 2.6 | 1,740 | NCT00114972 SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries |
| Semaglutide vs Insulin Aspart: deaths from any cause | 12 of 874 1 of 864 | 1.3 points 0.5 to 2.3 | 1,738 | NCT03689374 A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes |
| Semaglutide vs Insulin Aspart: serious adverse events | 65 of 874 84 of 864 | -2.3 points -4.9 to 0.4 | 1,738 | NCT03689374 A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes |
| BG00012 240 mg BID vs BG00012 240 mg TID: Number of Participants With Treatment-Emergent Adverse Events (AEs) | 824 of 868 814 of 868 | 1.2 points -1.0 to 3.4 | 1,736 | NCT00835770 BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) |
| BG00012 240 mg BID vs BG00012 240 mg TID: deaths from any cause | 5 of 868 6 of 868 | -0.1 points -1.0 to 0.7 | 1,736 | NCT00835770 BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) |
| BG00012 240 mg BID vs BG00012 240 mg TID: serious adverse events | 279 of 868 272 of 868 | 0.8 points -3.6 to 5.2 | 1,736 | NCT00835770 BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) |
| INV_MMR vs COM_MMR: Number of Subjects Reporting Any Serious Adverse Events (SAEs) | 24 of 1,164 9 of 572 | 0.5 points -1.1 to 1.7 | 1,736 | NCT02184572 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age |
| INV_MMR Group vs COM_MMR Group: Number of Subjects Reporting Any Unsolicited AEs | 598 of 1,164 277 of 572 | 2.9 points -2.1 to 7.9 | 1,736 | NCT02184572 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age |
| INV_MMR Group vs COM_MMR Group: serious adverse events | 24 of 1,164 9 of 572 | 0.5 points -1.1 to 1.7 | 1,736 | NCT02184572 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age |
| Umbilical Cord Milking - Neonates vs Early Cord Clamping - Neonates: Number of Neonatal Deaths | 0 of 872 4 of 858 | -0.5 points -1.2 to 0.1 | 1,730 | NCT03631940 Umbilical Cord Milking in Non-Vigorous Infants |
| Umbilical Cord Milking-Neonates vs Early Cord Clamping-Neonates: deaths from any cause | 0 of 872 4 of 858 | -0.5 points -1.2 to 0.1 | 1,730 | NCT03631940 Umbilical Cord Milking in Non-Vigorous Infants |
| Umbilical Cord Milking-Neonates vs Early Cord Clamping-Neonates: serious adverse events | 1 of 872 2 of 858 | -0.1 points -0.7 to 0.4 | 1,730 | NCT03631940 Umbilical Cord Milking in Non-Vigorous Infants |
Code
curl "https://conductscience.org/api/comparisons/v1?page=196"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=196
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02284191-sae",
"title": "CT Coronary Angiogram vs Standard Care: serious adverse events",
"summary": "18 of 877 against 10 of 871; risk difference 0.9 points, 95% interval -0.3 to 2.2; NCT02284191, Rapid Assessment of Potential Ischaemic Heart Disease With CTCA",
"record": "/library/comparisons/NCT02284191-sae",
"nct_id": "NCT02284191",
"kind": "serious-adverse-events",
"participants": 1748,
"risk_difference": {
"value": 0.009043459136210885,
"lower": -0.003080320083924594,
"upper": 0.021846789965071407
},
"group_1": "18 of 877",
"group_2": "10 of 871",
"difference": "0.9 points",
"interval": "-0.3 to 2.2",
"trial_title": "Rapid Assessment of Potential Ischaemic Heart Disease With CTCA"
},
{
"id": "NCT02648347-deaths",
"title": "Vadadustat vs Darbepoetin Alfa: deaths from any cause",
"summary": "180 of 878 against 168 of 870; risk difference 1.2 points, 95% interval -2.6 to 4.9; NCT02648347, Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease",
"record": "/library/comparisons/NCT02648347-deaths",
"nct_id": "NCT02648347",
"kind": "deaths",
"participants": 1748,
"risk_difference": {
"value": 0.011907941245778014,
"lower": -0.025562625627787633,
"upper": 0.04932099987997881
},
"group_1": "180 of 878",
"group_2": "168 of 870",
"difference": "1.2 points",
"interval": "-2.6 to 4.9",
"trial_title": "Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=197",
"request_id": "J4Hxs7n2A6tB4uW8"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant